In conclusion, we suggested that biomarker risk score for cumulative cardiovascular events, constructed by measurement of circulating NT-pro-BNP, galectin-3, hs-CRP, osteoprotegerin, CD31+/annexin V+ EMPs and EMPs/CD14 + CD309+ MPCs ratio, allowing reliably predict the probability survival of patients with CHF, regardless of age, gender, state of the contractile function of the left ventricle and the number of comorbidities. This evidence concerns the gene PECAM1 and congestive heart failure.